Vyhledávání, rešerše a další informačně-knihovnické služby v oblastech competitive intelligence

Papík, Richard
2016

Vyhledávání, rešerše a další informačně-knihovnické služby v oblastech competitive intelligence

Richard Papík

- Ústav bohemistiky a knihovnictví FPF Slezské univerzity
- Ústřední knihovna Univerzity Karlovy

http://www.linkedin.com/in/papik
http://www.facebook.com/richard.papik

Searching Session 2016

Akce konaná v úterý 4.10. 2016 v Národní technické knihovně v Praze, venku nádherně deštivo, což je přímo ideální pro seminář nebo četbu ...


TAJNÉ
"GOSSIP"
ŠEDÁ ZÓNA
(ZDROJE ŠEDÉ LITERATURY)
FYZICKÝ A ELEKTRONICKÝ INF. PROSTOR

?

Co je competitive intelligence a co možná není, a také co zásadně není…


WHAT's THE "Oi" (also Bi, Mi)?
REALLY NOT A SIMPLE ANSWER
STRATEGY: FINANCIAL... ANALYSIS
MANAGER'S GAME
(WAR)
btw: COMPETITIVE GAMES (~ GAME THEORY)
CORPORATE COMBAT
ETHIC
INFORMATION WORK / LIBRARIANSHIP
TEAM WORK
DIPLOMACY
CORPORATE INTELLIGENCE AND ESPIONAGE (INDUSTRIAL)
SIMILARITY WITH MILITARY (INTELLIGENCE)
"SYNONYMS" (SOMETIMES)
COMPETITIVE I.
COMPETITOR I.
COMPANY I.
CORPORATE I.
MARKET I.
BUSINESS I.
TODAY'S LECTURE
THEORY
CASES


INFORMACE
Z PROSTŘEDÍ
ROZŠIŘOVÁNÍ
SHROMAŽĎOVÁNÍ,
SBĚR
VYHLEDÁVÁNÍ
ANALYTICKO-
SYNTETICKÉ
ZPRACOVÁNÍ
ULOŽENÍ


zadání
výsledek
sběr
informací
zpracování

… důsledky pro profesi

Profese:

- Competitive Intelligence Professional
- Chief Information Officer
- Chief Knowledge Officer
- Research and Information Specialist
- Research Analyst
- Knowledge Analyst
- ale také Science Librarian, information officer ph.

Vztah ke knihovnicko-informační praxi:

- *http://www.sla.org, http://www.ala.org*
- *http://www.aiip.org,*
- *http://www.scip.org*

Kategorizace a výběrově příklady

- HUMINT
- GEOINT
- MASINT
- FININT
- TECHINT
- …
- **OSINT**

Typologie a vhodnost KI služeb, zkoumání informačního chování uživatelské skupiny

Umístění informačního brokeringu k informačnímu průmyslu



Jsou knihovny a jim podobné instituce vhodné pro služby uživatelům se vztahem k CI? … **jsou a jak** ☺

Komentování případových úloh …

Mapping the Indian nanotechnology innovation system

Article Options and Tools

View: HTML | PDF

References (16)

Add to Marked List | Download Citation | Track Citations | Reprints & Permissions

Author(s): Amit Kumar (Centre for Studies in Science Policy, Jawaharlal Nehru University, New Delhi, India)
Pranav N. Desai (Centre for Studies in Science Policy, Jawaharlal Nehru University, New Delhi, India)

Citation: Amit Kumar , Pranav N. Desai , (2014) "Mapping the Indian nanotechnology innovation system", World Journal of Science, Technology and Sustainable Development, Vol. 11 Iss: 1, pp.53 - 65

DOI http://dx.doi.org/10.1108/WJSTSD-09-2013-0039

Abstract:

Purpose

– The purpose of this paper is to map out the Indian nanotechnology innovation system. An attempt is made to identify the dominant actors, collaborative pattern and analyse the role of and interactions between the actors and institutions.

Design/methodology/approach

– A combination of frameworks such as national and international system of innovation is used to include all possible actors and institutions involved. A scientometric analysis is also carried out.

Findings

– Despite a series of government interventions discernible in various programmes since the 1980s, nanotechnology-based industries are yet to emerge as a dominant sector. The health sector has emerged as one of the major contributors in terms of nanotechnology applications. There are many other challenges of safety and standards, socioeconomic, ethical and environmental concerns. Academic R&D labs are active in technology transfer.

Research limitations/implications

– A scant literature is available for this sector in India and especially from the international innovation system framework to analyse the socioeconomic and risk governance issues.

Practical implications

– A scant literature is available for this sector in India and especially from the international innovation system framework to analyse the socioeconomic and risk governance issues.

Originality/value

– A scant literature is available for this sector in India and especially from the international innovation system framework to analyse the socioeconomic and risk governance issues.

Keywords: India, Nanotechnology, Innovation systems, International collaborations

Factors influencing the adoption of internet banking: a case study of commercial banks in Mauritius

Organization structure theories and open innovation paradigm

Clean energies development in built environment

The identity crisis of sustainable development

See More

Share

Further Information

About the Journal
Sample Articles
Purchase Information
Editorial Team
Write for this journal

World Journal of Science, Technology and Sustainable Development

ISSN: 2042-5945

Online from: 2010

Subject Area: Public Policy & Environmental Management

Mapping the Indian nanotechnology innovation system

Přepnuli jste do režimu celé obrazovky. Ukončit režim celé obrazovky (F11)

Mapping the Indian nanotechnology innovation system

Article Options and Tools

View: HTML | PDF

References (16)

Add to Marked List | Download Citation | Track Citations | Reprints & Permissions

Author(s): Amit Kumar (Centre for Studies in Science Policy, Jawaharlal Nehru University, New Delhi, Inc
Pranav N. Desai (Centre for Studies in Science Policy, Jawaharlal Nehru University, New Delh

Citation: Amit Kumar , Pranav N. Desai , (2014) "Mapping the Indian nanotechnology innovation system
of Science, Technology and Sustainable Development, Vol. 11 Iss: 1, pp.53 - 65

Downloads: The fulltext of this document has been downloaded 140 times since 2014

Abstract:

Purpose

– The purpose of this paper is to map out the Indian nanotechnology innovation system. An attempt is made to identify the dominant actors, collaborative pattern and analyse the role of and interactions between the actors and institutions.

Design/methodology/approach

– A combination of frameworks such as national and international system of innovation is used to include all possible actors and institutions involved. A scientometric analysis is also carried out.

Findings

– Despite a series of government interventions discernible in various programmes since the 1980s, nanotechnology-based industries are yet to emerge as a dominant sector. The health sector has emerged as one of the major contributors in terms of nanotechnology applications. There are many other challenges of safety and standards, socioeconomic, ethical and environmental concerns. Academic R&D labs are active in technology transfer.

Research limitations/implications

– A scant literature is available for this sector in India and especially from the international innovation system framework to analyse the socioeconomic and risk governance issues.

Practical implications

– A scant literature is available for this sector in India and especially from the international innovation system framework to analyse the socioeconomic and risk governance issues.

Originality/value

– A scant literature is available for this sector in India and especially from the international innovation system framework to analyse the socioeconomic and risk governance issues.

Keywords: India, Nanotechnology, Innovation systems, International collaborations

Publisher: Emerald Group Publishing Limited

Further Information

About the Journal

Sample Articles

Purchase Information

Editorial Team

Write for this journal

Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)	National Institutes of Health (NIH)
Components of Participating Organizations	National Institute of Biomedical Imaging and Bioengineering (NIBIB) National Cancer Institute (NCI) National Eye Institute (NEI) National Human Genome Research Institute (NHGRI) National Heart, Lung, and Blood Institute (NHLBI) National Institute on Aging (NIA)) National Institute on Alcohol Abuse and Alcoholism (NIAAA) National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institute on Drug Abuse (NIDA) National Institute on Deafness and Other Communication Disorders (NIDCD) National Institute on Dental and Craniofacial Research (NIDCR)) National Institute of Environmental Health Sciences (NIEHS) National Institute of Neurological Disorders and Stroke (NINDS) National Institute of Nursing Research (NINR)
Funding Opportunity Title	**Nanoscience and Nanotechnology in Biology and Medicine (R21)**
Activity Code	R21 Exploratory/Developmental Research Grant Award
Announcement Type	Reissue of PA-08-053
Related Notices	None
Funding Opportunity Announcement (FOA) Number	**PA-11-149**
Companion FOA	PA-11-148, R01 Research Project Grant
Number of Applications	See Section III. 3. Additional Information on Eligibility
Catalog of Federal Domestic Assistance (CFDA) Number(s)	93.286, 93.113, 93.867, 93.837, 93.172, 93.866, 93.173, 93.121, 93.113, 93.853, 93.279, 93.273, 93.361, 93.865, 93.846 93.855, 93.856
FOA Purpose	This initiative, issued by the National Institutes of Health, encourages applications from institutions/organizations that apply nanoscience and nanotechnology approaches to address problems in biology and medicine. The purpose of this FOA is to provide support for cutting-edge nanoscience and nanotechnology research that can lead to biomedical breakthroughs and new investigations into the diagnosis, treatment and management of an array of

Komplexnost, na klíč, s přidanou hodnotou apod.

Ambivalence a současně symbióza:

- end-user (koncový uživatel) - ?
- information broker (zprostředkovatel, prostředník) - ?
- end user x final user (koncový x konečný uživatel) - ? (Gartner, EIU aj.)


The Economist Intelligence Unit
The EIU
What we offer
Login/register
Contact us
Custom solutions
Our clients ask us to solve problems that are specific to them.
Whether it is deciding which Latin American country will provide the best operating environment for a logistics business, predicting which cities in China will emerge in the coming years to have the most favourable income levels and socio-demographics for a specific consumer product or assessing distribution channels in Africa for construction equipment, we can help.
Country and city forecasting
Our team comprises experts on every country in the world. If you need to know how quickly the US will grow over the next five years or what residential construction will take place in Saudi Arabia, we can help. Or in Thailand, Algeria or Kazakhstan. But sometimes five years is not enough.
Many of our clients have investment horizons measured in decades. Our proprietary methodologies let us look ahead 30 years or more, using frameworks you can understand and rely on.
And if countries are too broad for your business, we forecast growth, spending, income and investment in cities from Dongguan to Dhaka.
Contact us
Our site uses cookies
By continuing to browse the site you are agreeing to our use of cookies. Review our cookies information page for more details.
Close

Malé opakování:

Rešeršní strategie, které kladou důraz rovněž na analytický výběr zdroje




ProQuest
Help
Databases
Select the database(s) you would like to search, then click Continue
Search a single database by clicking on its name. Databases with checkboxes can be cross-searched.
Select all databases / Clear all databases
ABI/INFORM Dateline (ID 5921)
Business, Economics: local and regional business publications
Search a unique resource focusing on hard-to-find local and regional business news coverage of large corporations, privately held companies, local start-ups, executive profiles, marketing, finance, and industry news. Provides access to business information not typically found in national news sources. Contains news and analysis, information on local markets, and more gathered from major business tabloids, magazines, daily newspapers, wire services, and city, state, and regional business publications. more info...
Coverage: 1985-current | View titles
ABI/INFORM Global (ID 3)
Business, Finance, Economics: journals, company profiles, Wall Street Journal
Most scholarly and comprehensive way to explore and understand business research topics. Search nearly 3000 worldwide business periodicals for in-depth coverage of business and economic conditions, management techniques, theory, and practice of business, advertising, marketing, economics, human resources, finance, taxation, computers, and more. Expanded international coverage. Fast access to information on 60,000 + companies with business and executive profiles. Now includes The Wall Street Journal. more info...
Coverage: 1971 - current | View titles
ABI/INFORM Trade & Industry (ID 5820)
Business, Economics: trade and industry periodicals
Search more than 1200 business periodicals with a trade or industry focus. Provides users with the latest industry news, product and competitive information, marketing trends, and a wide variety of other topics. Contains publications on every major industry, including finance, insurance, transportation, construction, and many more. more info...
Coverage: 1971 - current | View titles
Academic Research Library (ID 4614)
Search for coverage of a broad range of subjects including arts, business, children, education, general interest, health, humanities, international, law, military, multicultural, psychology, sciences, social sciences, and women's interests. more info...
Coverage: 1971 - present | View titles
Accounting & Tax
Comprehensive coverage of accounting and tax topics appearing in key industry publications and newspapers. The quintessential accountant's database.
Coverage: varies | View titles
Accounting & Tax Newspapers (ID 4023)
Accounting, Taxation, Finance: newspapers
Search newspapers for the latest accounting and tax news.
Coverage: 1971 - current | View titles
Hotovo
Internet | Chráněný režim: Zapnuto
125%

Health: Journals, Magazines

Find complete, full-text information from covering numerous aspects of family health from sports injuries to women's health, from food and nutrition to midwifery, from eye care to dentistry.

Coverage: Varies | View titles

☑ **ProQuest Health and Medical Complete** (ID 4795)

Health, Medicine: Journals, Magazines

Designed to serve a wide range of people who need health information -- from hospital administrators to medical professionals to consumers. The database provides coverage from leading health journals and essential medical journals in key medical specialties. more info...

Coverage: varies | View titles

☑ **ProQuest Medical Library** (ID 2390)

Search a comprehensive database combining MEDLINE indexing with full images for more than 450 key medical titles. Offers coverage of all the major healthcare specialties, including nursing, pediatrics, neurology, pharmacology, cardiology, physical therapy, and others. more info...

Coverage: varies | View titles

☑ **ProQuest Military Collection** (ID 6960)

Search a comprehensive collection of material on military subjects such as defense, aeronautics and space flight, civil engineering, political science, and more. more info...

Coverage: varies | View titles

☑ **ProQuest Newspapers**

Search the full collection of newspapers.

Coverage: varies | View titles

☑ **ProQuest Newsstand** (ID 1906)

Full text of 300+ U.S. and international news sources. Includes coverage of 150+ major U.S. and international newspapers such as The New York Times and the Times of London, plus hundreds of other news sources and news wires. more info...

Coverage: varies | View titles

☑ **Advocate** (ID 13475)

Selectable newspaper subset. more info...

Coverage: varies | View titles

☑ **Chicago Tribune** (ID 541)

Provides reporting and analysis of regional, national, and international news. more info...

Coverage: 1985-current | View titles

☑ **Greenwich Time** (ID 13474)

Selectable newspaper subset.

Coverage: varies | View titles

Medical Evidence Matters

Medicine: Evidence-Based

A database designed to allow users to assess therapy options for known medical conditions by comparing outcomes from the peer-reviewed literature. more info...

Coverage: varies

Nursing & Allied Health Source

Search full-text journals and dissertations in ProQuest Nursing & Allied Health Source alongside Systematic Reviews, Evidence Summaries, and Best Practice Information Sheets from the renowned Joanna Briggs Institute.

Coverage: varies | View titles

ProQuest Nursing & Allied Health Source (ID 5441)

Nursing, Allied Health: Journals, Magazines, Dissertations

Find complete, full-text information from leading nursing, allied health, and related publications. Designed to meet the needs of researchers at health-care facilities as well as students enrolled in nursing and allied health programs at academic institutions. more info...

Coverage: varies | View titles

Pharmaceutical News Index (ID 2)

Search the definitive database of pharmacological news, research, and regulatory information. Covers the most important specialized publications in the pharmaceutical, health care, biotechnology, and medical device industries. more info...

Coverage: varies | View titles

ProQuest Asian Business and Reference (ID 2362)

Business, Finance, Economics: journals, magazines

Find the latest business and financial news from the Eastern Hemisphere. Covers Asian business and financial information from key international publications including Far Eastern Economic Review, Asiaweek, and many more. more info...

Coverage: 1971 - present | View titles

ProQuest Biology Journals (ID 5442)

Science, Biology: Journals and magazines

Search full-text journals in the life sciences. more info...

Coverage: 1998 - current | View titles

ProQuest Central (ID 25443)

ProQuest Central is the largest multidisciplinary database with over 12,665 titles, with over 9,745 titles in full-text. It serves as the central resource for researchers at all levels in all markets. Over 160 subjects areas are covered extensively in this product including business and economics, health and medical, news and world affairs, technology, social sciences and more.

Coverage: varies | View titles

ProQuest Computing (ID 3194)

Science, Technology: Journals and magazines

Search top computing journals in full text for research on subjects such as database design, software development, web commerce, LANs, WANs, Intranets, and the Internet. more info...

Coverage: 1998 - current | View titles

Life Science Intelligence; Valuations and Exit Strategies for Medtech Companies in the New Economy Analyzed in Online Industry Presentation by Medical Capital Advisors Chairman & CEO Christopher J.P. Velis

Anonymous. **Medical Devices & Surgical Technology Week**. Atlanta: Feb 14, 2010. pg. 572

Abstract (Summary)

2010 FEB 14 - (<http://www.newsrx.com> NewsRx.com) -- Life Science Intelligence (LSI) announced that medical technology investment banking veteran Christopher J.P. Velis of Medical Capital Advisors would kick off their Emerging Medical Technologies Spotlight - an online event showcasing 40 emerging medical device companies - with an industry presentation titled "Valuations and Exit Strategies for Medtech Companies in the New Economy: The 10 Things Every Startup, Investor, and Dealmaker Needs to Know." Mr. Velis' one-hour industry presentation, which will be released in an interactive webinar format, will provide startup CEOs, business development executives, and venture capitalists with a practical and realistic picture of what to expect in terms of valuations and exits in 2010. Mr. Velis' discussion will be followed by detailed business presentations from the CEOs of 40 privately-held emerging medical device companies selected by event host Life Science Intelligence. Each of the 40 presenting companies is seeking strategic partners and/or raising capital. Register here to access the event (see also <http://www.newsrx.com/library/topics/Life-Science-Intelligence.html> Life Science Intelligence).

» Jump to indexing (document details)

Full Text (567 words)

2010 FEB 14 - (<http://www.newsrx.com> NewsRx.com) -- Life Science Intelligence (LSI) announced that medical technology investment banking veteran Christopher J.P. Velis of Medical Capital Advisors would kick off their Emerging Medical Technologies Spotlight - an online event showcasing 40 emerging medical device companies - with an industry presentation titled "Valuations and Exit Strategies for Medtech Companies in the New Economy: The 10 Things Every Startup, Investor, and Dealmaker Needs to Know." Mr. Velis' one-hour industry presentation, which will be released in an interactive webinar format, will provide startup CEOs, business development executives, and venture capitalists with a practical and realistic picture of what to expect in terms of valuations and exits in 2010. Mr. Velis' discussion will be followed by detailed business presentations from the CEOs of 40 privately-held emerging medical device companies selected by event host Life Science Intelligence. Each of the 40 presenting companies is seeking strategic partners and/or raising capital. Register here to access the event (see also <http://www.newsrx.com/library/topics/Life-Science-Intelligence.html> Life Science Intelligence).

Attendees receive online access to Mr. Velis' presentation and 10-15 minute CEO presentations (audio and slides); a notebook of executive summaries; and detailed information, such as: development stage, competitive landscape and positioning, technological advantage, target markets, sales forecasts, financial and fund raising status, management team, IP position, exit strategy, and contact details.

Companies on the program thus far include: Aardvark Medical, Advanced Ophthalmic Pharma, Angel Medical Systems, ArtVentive Medical, Bakhtar Medical Imaging, Biomedix, Branching Tree, CardioMag, Cardious, Epinex Diagnostics, Heart Test Labs, Izun Pharmaceuticals, Lerner Medical Devices, LightIntegra, MEDTRONS, Mobius Therapeutics, Near Infrared Imaging, NuOrtho Surgical, Optical Imaging, Pico-Tesla Magnetic Therapies, PolyRemedy, Qscope, Renova Orthopedics, Sara Medical Devices, Seguro Surgical,

Other available formats:

Abstract

Find more documents like this:

Author(s):

Anonymous

Document types:

Expanded Reporting

Publication title:

Medical Devices & Surgical Technology Week

Search Clear


DataStar Web - Quick Search (MOJO) - Microsoft Internet Explorer
Soubor Úpravy Zobrazit Přejít Oblíbené Nápověda
Zpět Vpřed Stop Obnovit Domů Hledat Oblíbené Tisk Písmo Pošta
Adresa http://dsweb.krinfo.ch/2010a1fb/WBSEARCH/3/e1633d69/
Odkazy
DATASTAR WEB
Logout
Back to Subjects
Databases
Advanced Search
Options
Costs
Help
Euromonitor Journals (MOJO)
Search tips:
For a list of words beginning with "employ" type employ?
To search for all words beginning with "employ" type employ$
OR two terms together like this: solar energy, solar power
Remove punctuation (e.g.) Knight Ridder Information not "Knight-Ridder Information"
Enter your search term(s) and choose the part of the document to be searched
beer$
Title
AND
german$
Title
Save Search
From date: 970501 (YYMMDD)
Search
Hotovo


DataStar Web - Titles (MOJO) - Microsoft Internet Explorer
Soubor Úpravy Zobrazit Přejít Oblíbené Nápověda
Zpět Vpřed Stop Obnovit Domů Hledat Oblíbené Tisk Písmo Pošta
Adresa http://dsweb.krinfo.ch/2010a1fb/WBSEARCHBUTTON/1001/e06c1fb7/
Odkazy
DATASTAR WEB
Logout
Back to Subjects
Databases
New Search
Options
Costs
Help
Euromonitor Journals (MOJO)
Your search for BEER$.TI. AND GERMAN$.TI. resulted in 1 document.
Documents 1 to 1 of 1:
1 table of contents
May 1997 (9705). THE GERMAN MARKET FOR BEER.
The documents will be shown in the following print-format:
Table-of-Contents Free Short Medium Long Bibliographic
The documents will be shown in the following output-format:
HTML Tagged
Attention:


DataStar Web - Titles (MOJO) - Microsoft Internet Explorer
Soubor Úpravy Zobrazit Přejít Oblíbené Nápověda
Zpět Vpřed Stop Obnovit Domů Hledat Oblíbené Tisk Písmo Pošta
Adresa http://dsweb.krinfo.ch/2010a1fb/WBSEARCHBUTTON/1001/e06c1fb7/
Odkazy
1 table of contents
May 1997 (9705). THE GERMAN MARKET FOR BEER.
The documents will be shown in the following print-format:
Table-of-Contents Free Short Medium Long Bibliographic
The documents will be shown in the following output-format:
HTML Tagged
Attention:
ERA Redistribution is not allowed for the following database(s): MOJO
ERA Archive is not allowed for the following database(s): MOJO
Help on ERA
View selected documents
View all documents on this page
Price of selected documents
Order selected documents
Sort titles
Title
Ascending
About DataStar Web | What's New | FAQs | Feedback
© 1997 Knight-Ridder Information


DataStar Web - Document(s) (MOJO) - Microsoft Internet Explorer
Soubor Úpravy Zobrazit Přejít Oblíbené Nápověda
Zpět Vpřed Stop Obnovit Domů Hledat Oblíbené Tisk Písmo Pošta
Adresa http://dsweb.krinfo.ch/2010a1fb/WBDOCUMENT/1002/b22d9b66/
Odkazy
Euromonitor Journals (MOJO)
Order_Document
Accession number & update
MRE0597C 970710.
Title
THE GERMAN MARKET FOR BEER.
Source
MARKET RESEARCH EUROPE
Euromonitor plc.
Publication date
May 1997 (9705).
Occurrences
PARAGRAPH
TI (1)
Length
181,390 Characters, approximately 107 PC screens Number of TX paragraphs: 41.
Country
GERMANY.
COPYRIGHT BY Euromonitor plc, London, UK
About DataStar Web | What's New | FAQs | Feedback
© 1997 Knight-Ridder Information

Identifikace jádra informačních zdrojů, případové úlohy a jejich komentáře ...

STN on the web

- About
- First Time User
- Free Search Preview
- Customer Support
- Get Structure Plug-in
- Get Sequence Plug-in
- Standard Login
- Academic Login
- Secure Session
- STN Links
- Feedback

Your search preview results are shown below.

The selected field of interest is "MEDICINE" (Medicine and Medical Science Cluster)
The selected databases are: MEDICINE

Search Terms: hepsera

Answers	Databases
22	NLDB
18	EMBASE
16	PHIN
8	TOXCENTER
7	ADISNEWS
7	IPA
7	PHARMAML
6	DRUGNL
4	ADISCTI
3	BIOTECHNO
2	ADISINSIGHT
2	DRUGLAUNCH
2	DRUGMONOG2
2	SCISEARCH
1	MEDLINE
1	PASCAL

Bibliometrické nástroje analytické a kreativní hledání souvislostí: některé mizí, jiné přichází

- STN Index
- Dialindex ☹ -- zrušen
- Dialog Company Name Finder
- Dialog Product Name Finder
- Dialog Journal Name Finder … vše zrušeno

Ale …

Home > Products > STN

STN® AnaVist™

Analysis and visualization software for information professionals

Features and Benefits

- Analyze the patent landscape to determine emerging trends and leaders.
- Stay ahead of your competitors.
- Support strategic business planning.
- Integrate content from multiple databases.
- Quickly view interactive relationships among data and charts.

STN® AnaVist™ was designed for use with STN Express® or STN® on the Web℠ to search indexed, full-text patent databases (2AnaVist):

- CAplus℠ - Chemical Abstracts Plus
- EPFULL - European Patents Fulltext
- PCTFULL - WIPO/PCT Patents Full Text
- USPAT2 - U.S. Patents Latest Publications
- USPATFULL - U.S. Patents Original Publications
- WPINDEX - (WPIDS and WPIX subscribers will see the WPINDEX content)

New to STN AnaVist?

- Take a Test Drive of STN AnaVist (PDF)
- STN AnaVist Test Projects Request Form (PDF)
- STN AnaVist License Agreement (PDF)
- STN AnaVist CD-ROM Order Form (PDF)

STN Information

- Overview
- Content
- New STN
- Global Value Pricing
- Customer Support & Training
- STN News

STN News - What's New on STN

September, 2015 | PatentPak - A Time Saving Solution for IP Professionals - Is Coming to STN in Early 2016!

July/August, 2015 | Latest New STN Release Features Eight New Databases Including MARPAT from CAS for Markush Structure Searching

June, 2015 | CAS REGISTRY – 50 Years Strong, 100 Million Substances Driving Your Research

See More *STN News* >>

View or sign-up for *STN News* e-Newsletter


DISCOVER THOMSON REUTERS
GLOBAL - ENGLISH
LOGIN
CONTACT
SUPPORT
the answer company
THOMSON REUTERS
Products & Services
About Us
Careers
Search
Home › Products & Services › Intellectual Property › Patent Research and Analysis › Thomson Data Analyzer
Share
Thomson Data Analyzer
IP analysis made easy
Description:
Thomson Data Analyzer™ desktop software offers a powerful interface for managing and extracting business-critical insights from patent and scientific data within in-house or commercial databases.
With its advanced analysis technology, Thomson Data Analyzer empowers users to analyze patent data and scientific literature from any structured database directly on their desktop. It allows you to cut through masses of data to give you clear and definitive insights - at a glance.
Thomson Data Analyzer provides an easy way to analyze trends, profile competitors, avoid or uncover patent and copyright infringement, and identify strategic development opportunities in information.
Contact Sales ›
Features
Benefits
Already a Customer

Příklad: ProQuest



Příklad: I2 IBM



Příklad: Tovek Tools



Případové úlohy a komentáře ...

Company Analysis

Drug development strategies of the key players in Pharmaceutical R&D..

Therapy Analysis

A therapeutic insight into R&D trends in the pharmaceutical industry..

Pharmaceutical R&D Pipeline News

Start Making Sense - Exon Skipping & Nonsense Suppression

A joint revolution in the treatment of genetic disease?

Twenty-two years ago, the largest gene found in nature was isolated, and a year later it was sequenced. This 2.4Mb leviathan encoded no mere housekeeping protein – its 3685-amino-acid product, a rod-shaped human muscle protein now known as dystrophin, is of profound significance to families affected by the various forms of muscular dystrophy, a disease which occurs in 1 in 3500 newborn males.

However, 22 years on, the slow progress of gene therapies to market has been profoundly disappointing in all sectors, not only for muscular dystrophy or other genetic diseases – as yet, following a quarter of a century of frenetic R&D activity, there are still only two gene therapies launched worldwide, and both of these are for cancer...

read full article >>

Mergers, Acquistions & Joint Ventures

Onyx Pharmaceuticals has acquired **Proteolix**.

ACE Biosciences has becmoe a subsidiary of **Zymenex**.

GPC Biotech has merged into **Agennix**.

New Drug Targets

Newly identified drug protein targets.

» endo/exonuclease (5'-3'), endonuclease G-like

Newsletter Signup

Email:

Company:

submit

Pharma R&D Pipeline Intelligence

Our pharmaceutical research commentary & drug development news are derived from Pharmaprojects' R&D pipeline intelligence data. Pharmaprojects' research & development pipeline intelligence is your answer to an increasingly competitive pharmaceutical market...

..more about us

Pharmaprojects*

*Subscriber access only

ProQuest Dialog

Description

Pharmaprojects provides up-to-date intelligence on new pharmaceutical products under development, from early pharmacological studies to launch. It covers pharmaceuticals as well as biotechnological products, new formulations and combinations under development anywhere in the world, from pre-clinical through all phases of clinical development, pre-registration, approval and launch. It also includes information on discontinued drugs.

Subject Coverage

Pharmaprojects primarily addresses the information needs of the pharmaceutical industry and closely related fields, but is also of interest to those involved in the evaluation of pharmaceutical company performance. Most documents contain the product name, synonyms, originating company and development status, licensees and development status, CAS® Registry Number, molecular formula, pharmacology and descriptive text.

Date Coverage

1981 to the present

Update Frequency

Weekly

Geographic Coverage

International

Document Types

Reports of drug development

Publisher

Pharmaprojects is provided by Informa UK Ltd. Questions concerning file content should be directed to:

Informa UK Ltd.
Pharmaprojects Helpdesk
69-77 Paul Street
London, EC2A 4LQ
United Kingdom

Telephone: +44 (0) 20 7017 6868
Fax: +44 (0) 20 7017 6905
E-Mail: pharmaprojects.help@informa.com

OVID

R & D Focus

<1993 to June 05, 2003>

Help

Search Fields | Combine | Limit | Basic | Logoff

#	Search History	Results	Display
-	-	-	-

Saved Searches

Enter **Keyword** or phrase:

hepsera

Perform Search

Limit to:

☐Latest Update ☐Image ☐Active Program

Version: rel6.1.0, SourceID 1.7672.1.63

OVID

R & D Focus
<1993 to June 05, 2003>

Help

Search Fields | Combine | Limit | Basic | Logoff

#	Search History	Results	Display
1	hepsera.mp. [mp=descriptor words, drug word, general comments, commercial summary]	1	Display

Saved Searches | Save Search History | Delete Searches

Enter **Keyword** or phrase:

Perform Search

Limit to:

☐Latest Update ☐Image ☐Active Program

Results of your search: **hepsera.mp. [mp=descriptor words, drug word, summary]**

Citation displayed: **1** of **1**

Main Search Page

Results of your search: **hepsera.mp. [mp=descriptor words, drug word, general comments, commercial summary]**

Citation displayed: **1** of **1**

Go to Record: 1 Go

Citation Manager • Help • Logoff

Customize Display | Reset Display

1. **Accession Number**: 2005664

Drug Name: adefovir dipivoxil (BAN)

Complete Reference • Image File (GIF)

Main Search Page

Citation Manager: Display, Print, Save, or Email Citations

Citations	Fields	Citation Format	Action
◉ Selected Citations ○ All in this set (1-1) and/or **Range:**	○ Citation (Title,Author,Source) ◉ Citation + Abstract ○ Citation + Abstract + Subject Headings ○ Complete Reference Select Fields	◉ Ovid ○ BRS/Tagged ○ Reprint/Medlars ○ Brief (Titles) Display ○ Direct Export ☐ Include Search History	Display Print Preview Save

Sort Keys

Primary:	-	Ascending
Secondary:	-	Ascending

Citation 1.

Link to... Image File (GIF)

Accession Number

2005664

Drug Name

adefovir dipivoxil (BAN)

Synonyms

GS 840, **HEPSERA**, RESPUR, PREVEON

Highest Phase

Marketed

Active Program

Yes

Chemical Name

2,2-dimethylpropanoic acid [[[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]phosphinylidene]bis (oxymethylene) ester

CAS Registry Numbers

142340-99-6 (adefovir dipivoxil), 220351-05-3 (cpd with succinic acid (1:1)), 220351-03-1 (fumarate (1:1)), 220351-10-0 (maleate (1:1)), 220351-14-4 (cpd with L-ascorbic acid (1:1)), 220351-22-4 (cpd with methanol (1:1)), 220350-43-6 (dihydrate), 220350-98-1 (monocamsilate), 220350-82-3 (monomesilate), 220350-60-7 (monohydrobromide), 220350-68-5 (monohydrochloride), 220350-82-3 (monoesilate), 220350-94-7 (mono-1-naphthalenesulfonate), 220350-89-0 (mononapsilate), 220350-73-2 (mononitrate), 220351-17-7 (mononicotinate), 220350-52-7 (sulfate (2:1))

General Comments

20030609 pc Launch. Gilead Sciences' reverse transcriptase inhibitor, adefovir dipivoxil (**HEPSERA**), has been launched in Germany for the treatment of chronic hepatitis B virus infection.

Company Information

Originator: Bristol-Myers Squibb, USA
Licensee: Gilead Sciences, USA
Licensee: GlaxoSmithKline, UK

Indication

cytomegalic inclusion disease, hepatitis, viral infection

EphMRA Code

J5B Antivirals, Excluding Anti-HIV Products

Latest Change

20030609

Commercial Summary

Gilead Sciences is developing a mononucleotide analogue, adefovir dipivoxil, an oral, once-daily prodrug of adefovir, for the treatment of viral infection. Applications for marketing approval of the agent in the treatment of chronic hepatitis B virus (HBV) infection, in treatment-naive and treatment-experienced patients, have been made in the USA and Europe (Gilead Sciences, MAR 2002). The US FDA approved the agent as a treatment for HBV infection and a launch has subsequently taken place in this market (Gilead Sciences, SEP 2002). The agent has also been approved in Europe as a treatment for HBV infection, and launches have taken place in the UK (Pharmaceutical Journal, APR 2003) and Germany (IMS, APR 2003). Filings have been submitted to regulatory authorities in Australia, Canada and Switzerland (Gilead Sciences, MAR 2003). An early access program was initiated in the USA for use of adefovir dipivoxil 10 mg in the treatment of patients with chronic HBV infection resistant to lamivudine and the program has been extended to Canada, Australia, and most European countries

Licensing Status

Unavailable for Licensing: Japan
Unavailable for Licensing: Taiwan
Unavailable for Licensing: South Korea
Unavailable for Licensing: China

Patent Assignee

Bristol-Myers Squibb

Patent Summary

Product: EP 481214 B 1998, priority US 583906 1990, designating 14 states. Equivalents identified in five countries.

Development Status

Marketed: USA, hepatitis
Phase III: USA, cytomegalic inclusion disease
Marketed: UK, hepatitis
Marketed: Germany, hepatitis
Registered: Europe, hepatitis
Pre-registration: Switzerland, hepatitis
Pre-registration: Canada, hepatitis
Pre-registration: Australia, hepatitis
Phase III: South-East Asia, hepatitis
Phase I: China, hepatitis

Substance Origin

chemical synthesis

Mechanism of Action

reverse transcriptase inhibitor, nucleotide analogue

Clinical Overview

In vitro, adefovir dipivoxil is effective against most drug-resistant HIV strains including with a Q151 mutation, and shows synergy with nucleoside analogues and proteinase inhibitors (Gilead Sciences, MAY 1997). Oral adefovir dipivoxil is rapidly converted to adefovir. Adefovir dipivoxil was associated with reduced p24 antigenemia and transient increases in CD4 counts in some patients infected with HIV. A phase I/II trial showed that once daily adefovir dipivoxil was safe and well tolerated at three different dose levels and caused a drug related decrease in p24 antigen levels in HIV-infected patients. Side effects included mild to moderate gastrointestinal symptoms. Oral bioavailability for adefovir dipivoxil was 40%. A phase I/II, trial showed adefovir dipivoxil at doses of 125 or 250 mg/day produced sustained increases in CD4 cell counts of 46 and 15 cells/mm3 from baseline, respectively, versus -41 cells/mm3 for placebo following 6 week treatment. Viral load, as measured by HIV RNA, was decreased by median -0.5 log copies/mL and -0.4 log copies/mL at the 125 and 250 mg doses, respectively. Detectable CMV levels were reduced in comparison with placebo in a subset of patients. In study 411 involving treatment-naive HIV-positive patients receiving adefovir dipivoxil, indinavir and one or two reverse transcriptase inhibitors (zidovudine, lamivudine or stavudine), or standard triple therapy (zidovudine, lamivudine and indinavir), 80% of patients receiving regimens with or without adefovir dipivoxil had undetectable levels of HIV RNA at 20 week. Triple drug regimens containing adefovir dipivoxil increased CD4 cells by 92 cells/mm3, compared with an increase of 66 cells/mm3 with the standard triple therapy. Elevations in liver transaminase and creatine kinase occurred in 8% and 3% of the adefovir dipivoxil group and 5% and 5% of the standard group, respectively (Gilead Sciences, APR 1998). In study 408, 442 HIV-positive patients were randomized to receive 120 mg adefovir dipivoxil (219 patients) or placebo (223 patients) once daily in addition to current antiretroviral therapy. In

Drug Development History

200304: Marketed, UK, Germany (HBV).
200303: Registered, Europe (HBV).
200211: Recommended, Europe (HBV).
200209: Registered and Marketed, USA (HBV).
200208: Recommended, USA (HBV).
200204: Licensing agreement between Gilead Sciences and GlaxoSmithKline.
200203: Pre-registration, USA, Europe (HBV).
200101: Phase I, China (HBV).
199912: Discontinued (HIV).
199910: Pre-registration, Europe (HIV). Approval not recommended, USA (HIV)
199904: Phase III, USA, Europe, Canada, Australia, Asia (HBV).
199903: Expanded access program expanded.
199901: Pre-registration, USA.
199811: Fast track designation.
199703: Phase II, USA, UK, Australia, Canada (HBV).
199701: Phase III, USA (HIV, CMV).
199606: Phase II/III, USA (HIV).
199504: Phase I/II, UK, (HBV).
199408: Phase I/II, USA (HIV).
199404: Phase I, USA.
199401: Preclinical, USA.
199009: Priority product patent application filed, USA.

Update Code

20030605

Děkuji Vám za pozornost.



Spojení: např. http//www.linkedin.com/in/papik